Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2010

View Archived Issues

Bezafibrate-medroxyprogesterone combination active against AML

MAC-13243 represents a new antibacterial class with Gram-negative selectivity

Neural stem cells used to deliver HER2-targeting antibodies

Glucobay OD approved in Japan for diabetes

Date set for FDA Advisory Committee review of tesamorelin

Genzyme reports fourth quarter 2009 results

Boehringer and Priaxon sign collaboration for mdm2/p53 inhibitors in cancer

Founders of Proteon Therapeutics launch new company Novita Therapeutics

Viralytics reports results from phase I trial of Cavatak in late-stage melanoma

Lecithin-based nanoparticle adjuvant induces antibody immune responses

Polylactide-co-glycolide cancer vaccine regulates dendritic cell network for antitumor responses

Idera achieves clinical milestone under Merck collaboration for cancer treatment

Abbott claims nicotinic alpha4beta2 receptor modulators as analgesics

New compounds for the treatment of neurodegeneration claimed by sanofi-aventis

Novel oncolytic agents described by Bristol-Myers Squibb

Ranbaxy acquires vaccine products and manufacturing facility from Biovel

MorphoSys enrolls first patient in phase Ib/IIa clinical trial for MOR-103

AstraZeneca claims mGluR2 agonists for the treatment of schizophrenia

Depomed plans for one additional phase III trial for menopausal hot flashes

Biotie reports topline data from VAP-1 antibody trial in RA patients

RXi and UMMS sign research collaboration for sd-rxRNA in ocular diseases

Merz and BioForm Medical sign agreement and plan of merger

GenVec enters collaboration for hearing loss treatments

Avir Green Hills Biotechnology commences phase II deltaFLU study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...